Decision: Unfavourable

Study Title:

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Secondor Third-Line Recurrent or Metastatic Cervical Cancer

  • NREC Code:

    22-NREC-CT-087

  • Decision:

    Unfavourable

  • Meeting Date:

    27/04/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Paula Calvert

  • PI Institution:

    University Hospital Waterford

  • Sponsor:

    Seagen Inc.

Scroll to Top
Skip to content